Martingale Asset Management L P Atea Pharmaceuticals, Inc. Transaction History

Martingale Asset Management L P

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$3.0 - $4.97 $528,555 - $875,639	-176,185 Reduced 81.46%	40,100 $134,000
Q4 2022 Feb 13, 2023	SELL	$4.35 - $6.17 $61,243 - $86,867	-14,079 Reduced 6.11%	216,285 $1.04 Million
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $461,928 - $739,590	84,140 Added 57.54%	230,364 $1.31 Million
Q2 2022 Aug 11, 2022	BUY	$5.33 - $8.18 $511 - $785	96 Added 0.07%	146,224 $1.04 Million
Q1 2022 May 12, 2022	BUY	$5.5 - $9.19 $269,780 - $450,778	49,051 Added 50.53%	146,128 $1.06 Million
Q4 2021 Feb 11, 2022	BUY	$7.67 - $44.59 $478,400 - $2.78 Million	62,373 Added 179.73%	97,077 $867,000
Q3 2021 Nov 12, 2021	BUY	$21.33 - $35.06 $740,236 - $1.22 Million	34,704 New	34,704 $1.22 Million

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $270M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.